Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-6

my take on it minus the garble;

has submitted its first clinical trial application in Germany (BfArM) for their evaluation and subsequent approval of the application.
This is a significant milestone establishing an agreed clinical and regulatory pathway with the European Medicines Agency
The Company is continuing to work with Parexel, in advancing the regulatory process and will continue to provide updates on material progress.In parallel the Company will reduce upfront capital requirements and extend its cash runway.
Capital management for sourcing future funding to be prudent given the present challenging market conditions.
Initiating the next clinical trial of ATL1102 in DMD as soon as possible to advance its clinical development
The Company expects to provide a more detailed program update in the coming weeks once the planning in line with the expectations noted above is sufficiently affirmed

once the paperwork is done for one submission it should be just a copy paste using similar / same materials for follow on submissions. I expect a solid news flow from here on it.